Q-omics provides the consensus-scored TAF13 profile across patient tissues and cancer cell-line models. TAF13 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TAF13 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TAF13 RNA expression shows 19,009 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where TAF13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF13 survival associations across molecular data types. TAF13 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF13 RNA expression–survival associations across cancer types. High TAF13 expression shows unfavorable associations in ACC, LIHC, MESO, LGG, BLCA and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TAF13 RNA expression.
This table summarizes TAF13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TAF13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF13 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, UCEC, LUAD and BRCA. The KICH box plot shows higher TAF13 RNA expression in normal versus tumor tissue (log2 FC = −1.911, t-test p < 0.001).
This table shows molecular features associated with TAF13 in patient tissues and cancer cell lines. In patient samples, TAF13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
